Skip to main content

Inflammatory

Inflammatory

Development of a New Class of Therapeutics to Treat Poisoning Diseases

Biotherapeutic for Systemic Sclerosis

TargetSite Therapeutics

To Identify a New Class of Therapeutics for Inflammatory Diseases

Allagium Therapeutics: Driving Change to Better Health

RIGImmune: Harnessing the Innate Immune System

Target Site Blocker (TSB) of the IL-17A-miR466I-3p iInteraction Prevents Progressive and Relapsing Remitting EAE

Novel RNA Therapeutics that Target RIG-I

Subscribe to Inflammatory